Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
TAK
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Last trade$21.66
Day change+$0.065 (+0.30%)
Day range$21.49 – $21.86
Volume2,036,383
Market cap$68.98B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for TAK.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for TAK.
Recent news
Company coverage with links to the original publishers.
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
ADMA Biologics shares gained 20.9% following better-than-expected Q3 2026 results. The company's lead product Asceniv drove revenue growth with a 31% year-over-year surge, while Bivigam sales declined 47.1% in the first nine months of 2026 due to competitive pressures. ADMA raised its minimum 2026 adjusted net income and EBITDA outlooks. Analysts recommend existing investors hold while new investors await a better entry point due to premium valuation.
Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.
Denali Therapeutics (DNLI) shares gained 7.8% after reporting Q3 results that beat expectations, with Avlayah revenues reaching $17.8 million and nearly fivefold growth from the previous quarter. The company expects Q4 revenues between $30-32 million and plans multiple 2027 pipeline readouts including an accelerated approval filing for zafinofusp alfa. Despite strong commercial uptake and $1.01 billion in cash, the stock carries a Zacks Rank #3 (Hold) rating due to pipeline setbacks and the loss of Takeda as a partner.
A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Mar 31, 2026
$0.3083
Jul 6, 2026
recurring
Sep 30, 2025
$0.3221
Dec 11, 2025
recurring
Mar 31, 2025
$0.339
Jul 7, 2025
recurring
Sep 30, 2024
$0.3261
Dec 12, 2024
recurring
Mar 27, 2024
$0.2922
Jul 8, 2024
recurring
Stock splits
Historical share-structure events and their execution dates.